Page 252 - ஒன்றுபட்டது மாநிலங்களில் பத்திரங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
VanGold Drills 674 gpt AgEq over 0 55m and 913 gpt AgEq over 0 75m
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
SilverSun Technologies Subsidiary Named to ChannelE2E Top 100 Vertical Market MSPs: 2021 Edition
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Chimes Media creating IMDb for music with cryptocurrency, smart contracts
You’re having a pint or two with some friends on a Friday night when the opening notes of a classic song begin playing. It takes everyone back and starts a conversation about the song and musician. Sooner or later some facts are in dispute. Who first recorded it? Did Sting every cover it? Didn’t Tiny Tim play the guitar on the live version recorded at Woodstock?
Joe Mohen wants to provide an easy way to settle that argument and give music fans so much more. Mr. Mohen is the founder and CEO of Chimes Media, holders of one of the largest datasets of music production credits. That forms the basis of a searchable database of music information and a marketplace of products appealing to music fans, including merchandise, public access to artists, and even a professional automated system to hire recording artists, composers, producers and others via blockchain-based smart contracts.
Share:
Extended safety analysis across eight studies helps further define the known safety profile of Olumiant 2-mg in atopic dermatitis
TORONTO, April 30, 2021 /CNW/ - Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company and Incyte s Olumiant® (baricitinib) 2-mg tablet taken once daily showed improvement in key measured treatment outcomes compared to placebo, and helped further characterize the long-term safety profile in adults with moderate- to severe atopic dermatitis (AD). In one BREEZE-AD5 analysis, Olumiant provided concurrent improvements in the severity and extent of AD, other key symptoms and quality of life as early as one week, as measured by per cent change from baseline compared to placebo. In a separate BREEZE-AD5 analysis, adults with AD on 10-50% of their bodies at baseline who were treated with Olumiant showed significant improvements in the severity and extent of disease comp
vimarsana © 2020. All Rights Reserved.